Evotec AG has signed a definitive agreement to acquire Kinaxo Biotechnologies GmbH, a Munich-based drug discovery alliance company, for $4.1 million in cash and an additional $5.4 million if performance-based milestones are achieved. With the acquisition, Evotec gains several technologies designed to help its partners make decisions earlier on drug efficacy, safety and patient response. The transaction is expected to close in April 2011. Kinaxo’s capabilities include Cellular Target Pro...